Arbutus Biopharma Corp's ability to collect accounts receivable sequentially worsen to 5.84, pointing to a challenging and on top of that deteriorating business climate for the Major Pharmaceutical Preparations industry. Arbutus Biopharma's Accounts Receivable average collection period in the Mar 31 2026 quarter, has increased to 63 days, from 26 days, in the Dec 31 2025 quarter.

If we take a look into Healthcare sector 385 other companies have achieved higher receivables turnover ratio. While receivables turnover ratio total ranking has improved thus far to 2399, from overall ranking in the fourth quarter 2025 at 2726.

What is Receivable Turnover Ratio?
What is Arbutus Biopharma Corp Selling?

What is Receivable Turnover Ratio?

Select the Comparisons :

None ▼

Select the Ratio:

Accounts Receivables Turnover▼

None ▼

Accounts Receivables Turnover▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

ABUS Receivables Turnover Ratio	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter	(Mar 31 2025) I. Quarter
Y / Y Receivable Change	9191.04 %	-84.79 %	-36.84 %	-45.57 %	-36.6 %
Y / Y Revenue Change	10054.54 %	-33.23 %	-60.49 %	522.19 %	15.14 %
Receivable Turnover Ratio (TTM)	5.84	14.04	10.28	9.65	3.49
ABUS's Total Ranking	# 2399	# 2726	# 3000	# 3329	#
Accounts Receivable average collection period days	62	26	36	38	104
Seq. Receivable Change	42700.73 %	-75.1 %	7.11 %	-18.6 %	-29.95 %
Seq. Revenue Change	16943.39 %	98.68 %	-95.07 %	508.79 %	12.07 %

Receivable Turnover Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 121
Healthcare Sector	# 386
Overall Market	# 2399

Receivable Turnover Ratio Statistics
High	Average	Low
24.12	8.03	3.12
(Dec 31 2022)		(Dec 31 2024)

ABUS Company Profile • Back to ABUS Efficiency Comparisons • Compare ABUS Receivables Turnover Ratio to its Competitors

Financial Statements
Arbutus Biopharma's Accounts Receivable	$ 128 Millions	Visit ABUS's Balance sheet
Arbutus Biopharma's Sales TTM	$ 191 Millions	Visit ABUS's Income Statement
Sources of ABUS's Revenues		Visit ABUS's Sales by Geography

Other Accounts Receivable Turnover Ratios
Major Pharmaceutical Preparations Industry Accounts Receivable Turnover Trends and Statistics
Healthcare Sector Accounts Receivable Turnover Statistics
Accounts Receivables Turnover Trends for overall market
ABUS's Receivable Turnover Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Accounts Receivables Turnover
Lowest Ranking Accounts Receivables Turnover

You may also want to know
ABUS's Growth Rates	ABUS's Roa	ABUS's Inventory Turnover Ratio	ABUS's Dividend Comparisons
ABUS's Profitability Ratios	ABUS's Roi	ABUS's Asset Turnover Ratio	ABUS's Dividend Growth
ABUS's Valuation Ratios	ABUS's Roe	ABUS's Financial Strength Ratios	ABUS's Dividend Payout Ratio

Companies with similar Receivables Turnover Ratio for the quarter ending Mar 31 2026, within Healthcare Sector	Receivable Turnover Ratio	Revenues for 12 Months ending Mar 31 2026	Receivable at quarter ending Mar 31 2026
Butterfly Network Inc	4.07	$ 102.639 Millions	$ 25.225 Millions
Inspiremd Inc	4.07	$ 10.044 Millions	$ 2.470 Millions
Pro dex Inc	4.05	$ 74.636 Millions	$ 18.438 Millions
Dexcom Inc	4.05	$ 4,817.200 Millions	$ 1,190.775 Millions
Gyre Therapeutics Inc	4.04	$ 117.049 Millions	$ 28.979 Millions
Ironwood Pharmaceuticals inc	4.03	$ 361.514 Millions	$ 89.782 Millions
Immunitybio inc	4.02	$ 140.977 Millions	$ 35.064 Millions
Upstream Bio Inc	4.00	$ 3.322 Millions	$ 0.831 Millions
Dyadic International Inc	3.97	$ 3.808 Millions	$ 0.959 Millions
Newamsterdam Pharma Company N v	3.93	$ 22.565 Millions	$ 5.739 Millions
Iovance Biotherapeutics inc	3.93	$ 285.608 Millions	$ 72.726 Millions
Teva Pharmaceutical Industries Limited	3.91	$ 14,139.000 Millions	$ 3,619.000 Millions
Precigen Inc	3.86	$ 31.595 Millions	$ 8.185 Millions
Outset Medical Inc	3.84	$ 116.783 Millions	$ 30.376 Millions
Insight Molecular Diagnostics Inc	3.79	$ 1.949 Millions	$ 0.514 Millions
Biomarin Pharmaceutical Inc	3.75	$ 3,242.316 Millions	$ 864.562 Millions
Adma Biologics Inc	3.75	$ 507.766 Millions	$ 135.423 Millions
Akebia Therapeutics Inc	3.74	$ 232.404 Millions	$ 62.150 Millions
Procept Biorobotics Corporation	3.72	$ 321.012 Millions	$ 86.311 Millions
Waters Corporation	3.71	$ 3,770.581 Millions	$ 1,015.109 Millions
Eli Lilly And Company	3.71	$ 72,249.500 Millions	$ 19,498.700 Millions
Align Technology inc	3.69	$ 4,094.492 Millions	$ 1,110.613 Millions
Ani Pharmaceuticals Inc	3.64	$ 923.706 Millions	$ 253.696 Millions
Evofem Biosciences Inc	3.61	$ 20.237 Millions	$ 5.602 Millions
Cytek Biosciences Inc	3.56	$ 202.548 Millions	$ 56.819 Millions
Dbv Technologies S a	3.55	$ 5.783 Millions	$ 1.631 Millions
Elite Pharmaceuticals Inc	3.54	$ 147.000 Millions	$ 41.503 Millions
Xencor Inc	3.52	$ 97.360 Millions	$ 27.665 Millions
Lifeward ltd	3.51	$ 20.923 Millions	$ 5.955 Millions
Coherus Oncology inc	3.46	$ 46.883 Millions	$ 13.558 Millions

Date modified: 2026-06-24T02:44:34+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.